{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:45:13Z","timestamp":1792514713482,"version":"4.5.0"},"reference-count":260,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012088","name":"Arcadia Fund","doi-asserted-by":"publisher","award":["S2022\/BMD-7229"],"award-info":[{"award-number":["S2022\/BMD-7229"]}],"id":[{"id":"10.13039\/100012088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB16\/11\/00303"],"award-info":[{"award-number":["CB16\/11\/00303"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2023-150993OB-I00"],"award-info":[{"award-number":["PID2023-150993OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.pharmthera.2025.108973","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:07:26Z","timestamp":1767629246000},"page":"108973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["SGLT2 inhibitors: Do they have antiarrhythmic properties?"],"prefix":"10.1016","volume":"279","author":[{"given":"Ricardo","family":"Caballero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tamargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Delp\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pharmthera.2025.108973_bb0005","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/jce.16544","article-title":"Impact of sodium-glucose co-transporter 2 inhibitors on atrial fibrillation recurrence post-catheter ablation among patients with type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"36","author":"Abdelhadi","year":"2025","journal-title":"Journal of Cardiovascular Electrophysiology"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108973_bb0010","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jacep.2023.06.008","article-title":"Impact of SGLT2 inhibitors on AF recurrence after catheter ablation in patients with type 2 diabetes","volume":"9","author":"Abu-Qaoud","year":"2023","journal-title":"JACC. Clinical Electrophysiology"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108973_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165770","article-title":"SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models","volume":"1866","author":"Andreadou","year":"2020","journal-title":"Biochimica Et Biophysica Acta. Molecular Basis of Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bib1283","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12933-019-0980-4","article-title":"Sodium-glucose cotransporter 2 inhibitor dapagliflozin attenuates diabetic cardiomyopathy","volume":"19","author":"Arow","year":"2020","journal-title":"Cardiovascular Diabetology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb0020","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jdiacomp.2018.02.004","article-title":"Diabetes mellitus, blood glucose and the risk of atrial fibrillation: A systematic review and meta-analysis of cohort studies","volume":"32","author":"Aune","year":"2018","journal-title":"Journal of Diabetes and its Complications"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108973_bb0025","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.numecd.2018.02.011","article-title":"Diabetes mellitus and the risk of sudden cardiac death: A systematic review and meta-analysis of prospective studies","volume":"28","author":"Aune","year":"2018","journal-title":"Nutrition, Metabolism, and Cardiovascular Diseases: NMCD"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119440","article-title":"Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia","volume":"276","author":"Azam","year":"2021","journal-title":"Life Sciences"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108973_bb0035","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb0040","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005686","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: A systematic review and Meta-analysis","volume":"6","author":"Baker","year":"2017","journal-title":"Journal of the American Heart Association"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108973_bb0045","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/dom.16107","article-title":"SGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and\/or obesity: A systematic review and network meta-analysis","volume":"27","author":"Bao","year":"2025","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb0050","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.hrthm.2014.11.009","article-title":"Cardiac late Na+ current: Proarrhythmic effects, roles in long QT syndromes, and pathological relationship to CaMKII and oxidative stress","volume":"12","author":"Belardinelli","year":"2015","journal-title":"Heart Rhythm"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108973_bb0055","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400147","article-title":"Ertugliflozin to reduce arrhythmic burden in patients with ICDs\/CRT-ds","volume":"3","author":"Benedikt","year":"2024","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.physiol.70.113006.100455","article-title":"Calcium cycling and signaling in cardiac myocytes","volume":"70","author":"Bers","year":"2008","journal-title":"Annual Review of Physiology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108973_bb0065","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/dom.14074","article-title":"Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study","volume":"22","author":"Birkeland","year":"2020","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12933-020-01208-z","article-title":"Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF","volume":"20","author":"Bode","year":"2021","journal-title":"Cardiovascular Diabetology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0075","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/ejhf.1663","article-title":"Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: Data from the EMPA-REG OUTCOME trial","volume":"22","author":"B\u00f6hm","year":"2020","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0080","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fphys.2019.00135","article-title":"The association between diabetes mellitus and atrial fibrillation: Clinical and mechanistic insights","volume":"10","author":"Bohne","year":"2019","journal-title":"Frontiers in Physiology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108973_bb0085","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes & Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12933-021-01243-4","article-title":"SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system","volume":"20","author":"Bonora","year":"2021","journal-title":"Cardiovascular Diabetology"},{"issue":"21","key":"10.1016\/j.pharmthera.2025.108973_bb0095","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMra2115011","article-title":"Gliflozins in the management of cardiovascular disease","volume":"386","author":"Braunwald","year":"2022","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108973_bb0100","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/ejhf.2381","article-title":"Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: Insights from DAPA-HF","volume":"24","author":"Butt","year":"2022","journal-title":"European Journal of Heart Failure"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0105","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","article-title":"Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) Inflammasome activation in heart failure","volume":"13","author":"Byrne","year":"2020","journal-title":"Circulation. Heart Failure"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fcdhc.2025.1537005","article-title":"Effect of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, on ventricular repolarization electrocardiographic parameters in type 2 diabetes patients: DAPA - ECG study","volume":"6","author":"Campos","year":"2025","journal-title":"Frontiers in Clinical Diabetes and Healthcare"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108973_bb0115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s13300-011-0003-2","article-title":"Evaluation of the effect of dapagliflozin on cardiac repolarization: A thorough QT\/QTc study","volume":"2","author":"Carlson","year":"2011","journal-title":"Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0120","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12933-023-01970-w","article-title":"Left ventricular remodeling response to SGLT2 inhibitors in heart failure: An updated meta-analysis of randomized controlled studies","volume":"22","author":"Carluccio","year":"2023","journal-title":"Cardiovascular Diabetology"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1012220","article-title":"In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study","volume":"9","author":"Cesaro","year":"2022","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb0130","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/jce.16621","article-title":"The impact of SGLT2 inhibitors on atrial fibrillation recurrence and Long-term clinical outcomes in HFrEF patients undergoing Cryoballoon ablation: A new frontier beyond diabetes and heart failure","volume":"36","author":"Cetin","year":"2025","journal-title":"Journal of Cardiovascular Electrophysiology"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108973_bb0135","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.hrthm.2024.05.063","article-title":"Sudden cardiac death due to ventricular arrhythmia in diabetes mellitus: A bench to bedside review","volume":"21","author":"Chakraborty","year":"2024","journal-title":"Heart Rhythm"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0140","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12933-022-01549-x","article-title":"The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: A nationwide cohort study","volume":"21","author":"Chan","year":"2022","journal-title":"Cardiovascular Diabetology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0145","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12933-021-01285-8","article-title":"The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor","volume":"20","author":"Chan","year":"2021","journal-title":"Cardiovascular Diabetology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb0150","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3892\/mmr.2024.13197","article-title":"Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (review)","volume":"29","author":"Chen","year":"2024","journal-title":"Molecular Medicine Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0155","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-020-01048-x","article-title":"The association between SGLT2 inhibitors and new-onset arrhythmias: A nationwide population-based longitudinal cohort study","volume":"19","author":"Chen","year":"2020","journal-title":"Cardiovascular Diabetology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0160","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-022-01480-1","article-title":"Direct cardiac effects of SGLT2 inhibitors","volume":"21","author":"Chen","year":"2022","journal-title":"Cardiovascular Diabetology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108973_bb0165","first-page":"729","article-title":"Empagliflozin ameliorates atrial and ventricular remodeling and arrhythmogenesis in an overweight rabbit model","volume":"40","author":"Cheng","year":"2024","journal-title":"Acta Cardiologica Sinica"},{"issue":"36","key":"10.1016\/j.pharmthera.2025.108973_bb0170","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","article-title":"Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF","volume":"42","author":"Curtain","year":"2021","journal-title":"European Heart Journal"},{"issue":"23","key":"10.1016\/j.pharmthera.2025.108973_bb0175","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.3390\/cells11233707","article-title":"Empagliflozin and dapagliflozin increase Na+ and inward rectifier K+ current densities in human cardiomyocytes derived from induced pluripotent stem cells (hiPSC-CMs)","volume":"11","author":"Dago","year":"2022","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108973_bb0180","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1001\/jamacardio.2022.3736","article-title":"Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction: A participant-level pooled analysis of DAPA-HF and DELIVER","volume":"7","author":"Desai","year":"2022","journal-title":"JAMA Cardiology"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0185","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3389\/fphys.2018.01303","article-title":"Myocyte [Na+]i dysregulation in heart failure and diabetic cardiomyopathy","volume":"9","author":"Despa","year":"2018","journal-title":"Frontiers in Physiology"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0190","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2017.05.032","article-title":"Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target","volume":"243","author":"Di Franco","year":"2017","journal-title":"International Journal of Cardiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108973_bb0195","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41569-022-00759-w","article-title":"Inflammatory signalling in atrial cardiomyocytes: A novel unifying principle in atrial fibrillation pathophysiology","volume":"20","author":"Dobrev","year":"2023","journal-title":"Nature Reviews. Cardiology"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108973_bb0200","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1113\/JP273048","article-title":"Calcium-mediated cellular triggered activity in atrial fibrillation","volume":"595","author":"Dobrev","year":"2017","journal-title":"The Journal of Physiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0205","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","article-title":"Hyperuricemia and its related diseases: Mechanisms and advances in therapy","volume":"9","author":"Du","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0210","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12933-024-02312-0","article-title":"The potential anti-arrhythmic effect of SGLT2 inhibitors","volume":"23","author":"Duan","year":"2024","journal-title":"Cardiovascular Diabetology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0215","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12933-018-0790-0","article-title":"A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats","volume":"17","author":"Durak","year":"2018","journal-title":"Cardiovascular Diabetology"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109617","article-title":"Dapagliflozin attenuates diabetic cardiomyopathy through erythropoietin up-regulation of AKT\/JAK\/MAPK pathways in streptozotocin-induced diabetic rats","volume":"347","author":"El-Sayed","year":"2021","journal-title":"Chemico-Biological Interactions"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb0225","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2337\/dc22-0714","article-title":"Sodium-glucose cotransporter 2 inhibitor treatment and risk of atrial fibrillation: Scandinavian cohort study","volume":"46","author":"Engstr\u00f6m","year":"2023","journal-title":"Diabetes Care"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108973_bb0230","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/j.jacc.2021.08.037","article-title":"Modulation of cardiac arrhythmogenesis by epicardial adipose tissue: JACC state-of-the-art review","volume":"78","author":"Ernault","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0235","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ehjcvp\/pvac043","article-title":"Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus","volume":"9","author":"Eroglu","year":"2022","journal-title":"European Heart Journal - Cardiovascular Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108973_bb0240","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/jcpt.13734","article-title":"Empagliflozin has favourable effect on frontal plane QRS-T angle in diabetic patients with cardiovascular disease","volume":"47","author":"Eyuboglu","year":"2022","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb0245","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/dom.14854","article-title":"Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database","volume":"25","author":"Fawzy","year":"2023","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0250","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvaf040","article-title":"Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: A meta-analysis of randomised controlled trials","author":"Fedele","year":"2025","journal-title":"European Heart Journal - Cardiovascular Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108973_bb0255","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Heart Rhythm"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb0260","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108973_bb0265","article-title":"Association between sodium-glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation","volume":"26","author":"Fichadiya","year":"2024","journal-title":"Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0270","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.dsx.2017.08.003","article-title":"SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms","volume":"12","author":"Filippatos","year":"2018","journal-title":"Diabetes & Metabolic Syndrome"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0275","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12933-024-02309-9","article-title":"Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: The EMPA-ICD trial","volume":"23","author":"Fujiki","year":"2024","journal-title":"Cardiovascular Diabetology"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.687256","article-title":"Electrical features of the diabetic myocardium. Arrhythmic and cardiovascular safety considerations in diabetes","volume":"12","author":"Gallego","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1011429","article-title":"Benefits of SGLT2 inhibitors in arrhythmias","volume":"9","author":"Gao","year":"2022","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0290","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4093\/dmj.2019.0185","article-title":"Mitochondrial mechanisms in diabetic cardiomyopathy","volume":"44","author":"Gollmer","year":"2020","journal-title":"Diabetes & Metabolism Journal"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108973_bb0295","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/FJC.0000000000001656","article-title":"Sodium glucose cotransporter 2 inhibitors improve long-term atrial fibrillation-free survival after catheter ablation","volume":"85","author":"Hakgor","year":"2025","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb0300","doi-asserted-by":"crossref","DOI":"10.4022\/jafib.20200502","article-title":"Effect of SLGT2 inhibitors on patients with atrial fibrillation","volume":"14","author":"Haloot","year":"2021","journal-title":"Journal of Atrial Fibrillation"},{"issue":"22","key":"10.1016\/j.pharmthera.2025.108973_bb0305","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022637","article-title":"Different responses of muscle sympathetic nerve activity to Dapagliflozin between patients with type 2 diabetes with and without heart failure","volume":"10","author":"Hamaoka","year":"2021","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132954","article-title":"Impact of sodium-glucose cotransporter 2 inhibitors on catheter ablation for atrial fibrillation in heart failure patients without type-2 diabetes","volume":"422","author":"Harada","year":"2025","journal-title":"International Journal of Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0315","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jacc.2015.04.056","article-title":"Atrial fibrillation activates AMP-dependent protein kinase and its regulation of cellular calcium handling: Potential role in metabolic adaptation and prevention of progression","volume":"66","author":"Harada","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"issue":"19","key":"10.1016\/j.pharmthera.2025.108973_bib1284","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.3390\/ijms221910842","article-title":"Empagliflozin relaxes resistance mesenteric arteries by stimulating multiple smooth muscle cell voltage-gated K+ (KV) channels","volume":"22","author":"Hasan","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108973_bb0320","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108973_bb0325","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/eurheartj\/ehab094","article-title":"Effects of dapagliflozin on mortality in patients with chronic kidney disease: A pre-specified analysis from the DAPA-CKD randomized controlled trial","volume":"42","author":"Heerspink","year":"2021","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0330","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.yjmcc.2019.01.001","article-title":"CaMKII signaling in heart diseases: Emerging role in diabetic cardiomyopathy","volume":"127","author":"Hegyi","year":"2019","journal-title":"Journal of Molecular and Cellular Cardiology"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108973_bb0335","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/CIRCULATIONAHA.121.057237","article-title":"Empagliflozin reverses late Na+ current enhancement and cardiomyocyte proarrhythmia in a translational murine model of heart failure with preserved ejection fraction","volume":"145","author":"Hegyi","year":"2022","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb0340","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 inhibitor-induced sympathoinhibition: A novel mechanism for cardiorenal protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC. Basic to Translational Science"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108973_bb0345","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1210\/clinem\/dgac402","article-title":"New-onset atrial fibrillation in patients with type 2 diabetes treated with novel glucose-lowering therapies","volume":"107","author":"Hsiao","year":"2022","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0350","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12933-021-01392-6","article-title":"Empagliflozin protects the heart against ischemia\/reperfusion-induced sudden cardiac death","volume":"20","author":"Hu","year":"2021","journal-title":"Cardiovascular Diabetology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb0355","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1002\/ehf2.13553","article-title":"Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: A crossover trial","volume":"8","author":"Ilyas","year":"2021","journal-title":"ESC Heart Failure"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108973_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101615","article-title":"Sodium-glucose Cotransporter-2 inhibitors and arrhythmias: A meta-analysis of 38 randomized controlled trials","volume":"4","author":"Jaiswal","year":"2025","journal-title":"JACC. Advances"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb0365","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/jpm12020271","article-title":"Clinical observation of SGLT2 inhibitor therapy for cardiac arrhythmia and related cardiovascular disease in diabetic patients with controlled hypertension","volume":"12","author":"Jhuo","year":"2022","journal-title":"Journal of Personalized Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108973_bb0370","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.3390\/ijms22116105","article-title":"Characteristics of ventricular electrophysiological substrates in metabolic mice treated with empagliflozin","volume":"22","author":"Jhuo","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"16","key":"10.1016\/j.pharmthera.2025.108973_bb0375","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.3390\/molecules25163606","article-title":"Effects of secretome from fat tissues on ion currents of cardiomyocyte modulated by sodium-glucose transporter 2 inhibitor","volume":"25","author":"Jhuo","year":"2020","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb0380","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s13238-020-00809-4","article-title":"Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis","volume":"13","author":"Jiang","year":"2022","journal-title":"Protein & Cell"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb0385","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ehjcvp\/pvad033","article-title":"Sodium-glucose cotransporter-2 inhibitors compared with glucagon-like-peptide-1 receptor agonists and out-of-hospital cardiac arrest in type 2 diabetes: A nationwide nested case-control study","volume":"9","author":"J\u00fal\u00edusd\u00f3ttir","year":"2023","journal-title":"European Heart Journal - Cardiovascular Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108973_bb0390","first-page":"543","article-title":"Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: Novel translational clues to explain EMPA-REG OUTCOME results","volume":"36","author":"Kang","year":"2020","journal-title":"The Canadian Journal of Cardiology"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108973_bb0395","doi-asserted-by":"crossref","first-page":"9559","DOI":"10.3390\/ijms23179559","article-title":"SGLT2 inhibitor empagliflozin modulates ion channels in adult zebrafish heart","volume":"23","author":"Karpushev","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108973_bb0400","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/s41440-025-02216-w","article-title":"Interaction between SGLT2 and the sympathetic nervous system in normal and various cardiovascular metabolic disease states","volume":"48","author":"Katsurada","year":"2025","journal-title":"Hypertension Research: Official Journal of the Japanese Society of Hypertension"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0405","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nature Communications"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108973_bb0410","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacep.2022.08.004","article-title":"Efficacy of sodium-glucose cotransporter 2 inhibitors on outcomes after catheter ablation for atrial fibrillation","volume":"8","author":"Kishima","year":"2022","journal-title":"JACC. Clinical Electrophysiology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb0415","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/01.RES.64.5.867","article-title":"On the mechanism of drug-induced blockade of Na+ currents: Interaction of antiarrhythmic compounds with DPI-modified single cardiac Na+ channels","volume":"64","author":"Kohlhardt","year":"1989","journal-title":"Circulation Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb0420","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","article-title":"Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase g\u03b1 oxidation","volume":"117","author":"Kolijn","year":"2021","journal-title":"Cardiovascular Research"},{"issue":"48","key":"10.1016\/j.pharmthera.2025.108973_bb0425","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1093\/eurheartj\/ehab420","article-title":"Effects of canagliflozin on human myocardial redox signalling: Clinical implications","volume":"42","author":"Kondo","year":"2021","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104870","article-title":"Empagliflozin protects heart from inflammation and energy depletion via AMPK activation","volume":"158","author":"Koyani","year":"2020","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0435","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.amjcard.2022.05.017","article-title":"Effect of sodium-glucose cotransporter inhibitors on major adverse cardiovascular events and hospitalization for heart failure in patients with type 2 diabetes mellitus and atrial fibrillation","volume":"178","author":"Kwon","year":"2022","journal-title":"The American Journal of Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bib1282","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12933-020-01066-9","article-title":"Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia\/reperfusion injury","volume":"19","author":"Lahnwong","year":"2020","journal-title":"Cardiovascular Diabetology"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108973_bb0440","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1161\/CIRCRESAHA.117.310083","article-title":"Calcium signaling and cardiac arrhythmias","volume":"120","author":"Landstrom","year":"2017","journal-title":"Circulation Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0445","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12933-024-02311-1","article-title":"Empagliflozin\u2019s role in reducing ventricular repolarization heterogeneity: Insights into cardiovascular mortality decline from the EMPATHY-HEART trial","volume":"23","author":"Lauretti","year":"2024","journal-title":"Cardiovascular Diabetology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb0450","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41577-022-00714-3","article-title":"Inflammatory cytokines and cardiac arrhythmias: The lesson from COVID-19","volume":"22","author":"Lazzerini","year":"2022","journal-title":"Nature Reviews. Immunology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108973_bb0455","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10557-022-07319-x","article-title":"Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: A propensity score-matched study in Hong Kong","volume":"37","author":"Lee","year":"2023","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108973_bb0460","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3390\/ijms20071680","article-title":"Empagliflozin attenuates myocardial sodium and calcium dysregulation and reverses cardiac remodeling in Streptozotocin-induced diabetic rats","volume":"20","author":"Lee","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0465","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radical Biology & Medicine"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2025.108973_bb0470","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cell.2018.09.048","article-title":"Biological functions of autophagy genes: A disease perspective","volume":"176","author":"Levine","year":"2019","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb0475","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/eurjhf\/hfp191","article-title":"Functional effects of glucose transporters in human ventricular myocardium","volume":"12","author":"von Lewinski","year":"2010","journal-title":"European Journal of Heart Failure"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108973_bb0480","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/dom.14772","article-title":"Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS program and CREDENCE trial and meta-analysis","volume":"24","author":"Li","year":"2022","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0485","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovascular Diabetology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244689","article-title":"Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis","volume":"16","author":"Li","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0495","article-title":"Protective effects of sodium-glucose transporter 2 inhibitors on atrial fibrillation and atrial flutter: A systematic review and meta- analysis of randomized placebo-controlled trials","volume":"12","author":"Li","year":"2021","journal-title":"Frontiers in Endocrinology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0500","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12933-021-01293-8","article-title":"Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: A systematic review and meta-analysis","volume":"20","author":"Li","year":"2021","journal-title":"Cardiovascular Diabetology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108973_bb0505","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/FJC.0000000000001197","article-title":"Comparison of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide receptor agonists for atrial fibrillation in type 2 diabetes mellitus: Systematic review with network meta-analysis of randomized controlled trials","volume":"79","author":"Li","year":"2022","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0510","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12933-020-01105-5","article-title":"SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: A systematic review with meta-analysis of 16 randomized controlled trials","volume":"19","author":"Li","year":"2020","journal-title":"Cardiovascular Diabetology"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0515","article-title":"Direct cardiac actions of sodium-glucose cotransporter 2 inhibition improve mitochondrial function and attenuate oxidative stress in pressure overload-induced heart failure","volume":"9","author":"Li","year":"2022","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0520","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12933-024-02137-x","article-title":"Effect of SGLT-2 inhibitors on arrhythmia events: Insight from an updated secondary analysis of>80,000 patients (the SGLT2i-arrhythmias and sudden cardiac death)","volume":"23","author":"Liao","year":"2024","journal-title":"Cardiovascular Diabetology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108973_bb0525","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030552","article-title":"Differing efficacy of dapagliflozin versus empagliflozin on the risk of incident atrial fibrillation in patients with type 2 diabetes: A real-world observation using a nationwide, population-based cohort","volume":"13","author":"Lim","year":"2024","journal-title":"Journal of the American Heart Association"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0530","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13643-025-02766-7","article-title":"Redefining outcomes of ventricular arrhythmia for SGLT2 inhibitor medication in heart failure patients: A meta-analysis of randomized controlled trials","volume":"14","author":"Lin","year":"2025","journal-title":"Systematic Reviews"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0535","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12933-020-01162-w","article-title":"The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors","volume":"19","author":"Ling","year":"2020","journal-title":"Cardiovascular Diabetology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108973_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e16835","article-title":"Long-term efficacy of sodium-glucose cotransporter 2 inhibitor therapy in preventing atrial fibrillation recurrence after catheter ablation in type 2 diabetes mellitus patients","volume":"9","author":"Liu","year":"2023","journal-title":"Heliyon"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108973_bb0545","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circulation Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108973_bb0550","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: A state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC. Basic to Translational Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0555","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12933-023-01772-0","article-title":"Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A real-world population-based cohort study in Hong Kong","volume":"22","author":"Lui","year":"2023","journal-title":"Cardiovascular Diabetology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0560","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10557-022-07368-2","article-title":"Effect of Dapagliflozin on the outcome of radiofrequency catheter ablation in patients with type 2 diabetes mellitus and atrial fibrillation","volume":"38","author":"Luo","year":"2024","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108973_bb0565","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00210-022-02243-1","article-title":"Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction","volume":"395","author":"Ma","year":"2022","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108973_bb0570","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jacep.2018.08.014","article-title":"Electroanatomical remodeling of the atria in obesity: Impact of adjacent epicardial fat","volume":"4","author":"Mahajan","year":"2018","journal-title":"JACC Clinical Electrophysiology"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108973_bb0575","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.tcm.2022.04.003","article-title":"Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias","volume":"33","author":"Manolis","year":"2023","journal-title":"Trends in Cardiovascular Medicine"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106448","article-title":"Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes","volume":"184","author":"Marfella","year":"2022","journal-title":"Pharmacological Research"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108973_bb0585","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1111\/jce.16344","article-title":"SGLT2i effect on atrial fibrillation: A network meta-analysis of randomized controlled trials","volume":"35","author":"Mariani","year":"2024","journal-title":"Journal of Cardiovascular Electrophysiology"},{"issue":"23","key":"10.1016\/j.pharmthera.2025.108973_bb0590","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1093\/eurheartj\/ehaf167","article-title":"Cardiovascular disease in chronic kidney disease","volume":"46","author":"Marx-Sch\u00fctt","year":"2025","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb0595","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/cvr\/cvw009","article-title":"Nav1.5 N-terminal domain binding to \u03b11-syntrophin increases membrane density of human Kir2.1, Kir2.2 and Nav1.5 channels","volume":"110","author":"Matamoros","year":"2016","journal-title":"Cardiovascular Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108973_bb0600","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","article-title":"Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease","volume":"18","author":"Matsushita","year":"2022","journal-title":"Nature Reviews. Nephrology"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0605","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.yjmcc.2019.02.006","article-title":"The cardiomyocyte \u00abredox rheostat\u00bb: Redox signalling via the AMPK-mTOR axis and regulation of gene and protein expression balancing survival and death","volume":"129","author":"Meijles","year":"2019","journal-title":"Journal of Molecular and Cellular Cardiology"},{"issue":"31","key":"10.1016\/j.pharmthera.2025.108973_bb0610","first-page":"E2134","article-title":"Dynamic reciprocity of sodium and potassium channel expression in a macromolecular complex controls cardiac excitability and arrhythmia","volume":"109","author":"Milstein","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0615","doi-asserted-by":"crossref","first-page":"16113","DOI":"10.1038\/s41598-018-34305-x","article-title":"A reduced M1-like\/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition","volume":"8","author":"Miyachi","year":"2018","journal-title":"Scientific Reports"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb0620","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4330\/wjc.v16.i5.240","article-title":"Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives","volume":"16","author":"Mondal","year":"2024","journal-title":"World Journal of Cardiology"},{"issue":"16","key":"10.1016\/j.pharmthera.2025.108973_bb0625","doi-asserted-by":"crossref","first-page":"326","DOI":"10.21037\/atm.2017.06.27","article-title":"The role of reactive oxygen species in the pathophysiology of cardiovascular diseases and the clinical significance of myocardial redox","volume":"5","author":"Moris","year":"2017","journal-title":"Annals of Translational Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108973_bb0630","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jchf.2021.05.006","article-title":"Empagliflozin-induced changes in epicardial fat: The centerpiece for myocardial protection?","volume":"9","author":"Mullens","year":"2021","journal-title":"JACC. Heart Failure"},{"issue":"16","key":"10.1016\/j.pharmthera.2025.108973_bb0635","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1161\/CIRCULATIONAHA.122.057364","article-title":"Empagliflozin inhibits cardiac late sodium current by Ca\/calmodulin-dependent kinase II","volume":"146","author":"Mustroph","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108973_bb0640","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ehf2.12336","article-title":"Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes","volume":"5","author":"Mustroph","year":"2018","journal-title":"ESC Heart Failure"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108973_bb0645","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s00380-023-02298-x","article-title":"Effect of dapagliflozin on ventricular repolarization in patients with heart failure with reduced ejection fraction","volume":"38","author":"Nakase","year":"2023","journal-title":"Heart and Vessels"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0650","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCRESAHA.120.316363","article-title":"Molecular basis of atrial fibrillation pathophysiology and therapy: A translational perspective","volume":"127","author":"Nattel","year":"2020","journal-title":"Circulation Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb0655","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1152\/physrev.00014.2006","article-title":"Arrhythmogenic ion-channel remodeling in the heart: Heart failure, myocardial infarction, and atrial fibrillation","volume":"87","author":"Nattel","year":"2007","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0660","article-title":"SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: a meta-analysis","author":"Neuen","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0665","doi-asserted-by":"crossref","first-page":"14872","DOI":"10.1038\/s41598-018-33293-2","article-title":"Empagliflozin ammeliorates high glucose induced-cardiac dysfuntion in human iPSC-derived cardiomyocytes","volume":"8","author":"Ng","year":"2018","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bib1281","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.017483","article-title":"Canagliflozin suppresses atrial remodeling in a canine atrial fibrillation model","volume":"10","author":"Nishinarita","year":"2021","journal-title":"Journal of the American Heart Association"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108973_bb0670","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s00392-024-02389-3","article-title":"Efficacy of dapagliflozin in improving arrhythmia-related outcomes after ablation for atrial fibrillation: A retrospective single-center study","volume":"113","author":"Noh","year":"2024","journal-title":"Clinical Research in Cardiology: Official Journal of the German Cardiac Society"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb0675","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/dom.13627","article-title":"Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study","volume":"21","author":"Norhammar","year":"2019","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"10365","key":"10.1016\/j.pharmthera.2025.108973_bb0680","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb0685","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/jce.15894","article-title":"SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: Meta-analysis of randomized clinical trials","volume":"34","author":"Oates","year":"2023","journal-title":"Journal of Cardiovascular Electrophysiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108973_bb0690","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266046","article-title":"Chronic kidney disease and atrial fibrillation: A dangerous combination","volume":"17","author":"Ocak","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0695","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/dom.14211","article-title":"Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials","volume":"23","author":"Okunrintemi","year":"2021","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.106159","article-title":"Effects of sodium\/glucose cotransporter inhibitors on atrial fibrillation and stroke: A meta-analysis","volume":"31","author":"Ong","year":"2022","journal-title":"Journal of Stroke and Cerebrovascular Diseases: The Official Journal of National Stroke Association"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb0705","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0710","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12933-023-01860-1","article-title":"Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: A systematic review","volume":"22","author":"Ouyang","year":"2023","journal-title":"Cardiovascular Diabetology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0715","doi-asserted-by":"crossref","first-page":"53","DOI":"10.33963\/KP.15666","article-title":"Empagliflozin significantly attenuates sotalol-induced QTc prolongation in rats","volume":"79","author":"\u00d6zg\u00fcr Bar\u0131\u015f","year":"2021","journal-title":"Kardiologia Polska"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0720","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00395-023-01022-0","article-title":"Acute antiarrhythmic effects of SGLT2 inhibitors-dapagliflozin lowers the excitability of atrial cardiomyocytes","volume":"119","author":"Paasche","year":"2024","journal-title":"Basic Research in Cardiology"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108973_bb0725","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/ejhf.1328","article-title":"Empagliflozin directly improves diastolic function in human heart failure","volume":"20","author":"Pabel","year":"2018","journal-title":"European Journal of Heart Failure"},{"issue":"16","key":"10.1016\/j.pharmthera.2025.108973_bb0730","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","article-title":"Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure","volume":"136","author":"Packer","year":"2017","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108973_bb0735","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ejhf.1732","article-title":"Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium-glucose cotransporter 2 inhibitors","volume":"22","author":"Packer","year":"2020","journal-title":"European Journal of Heart Failure"},{"issue":"48","key":"10.1016\/j.pharmthera.2025.108973_bb0740","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1093\/eurheartj\/ehad235","article-title":"Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors","volume":"44","author":"Packer","year":"2023","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb0745","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jacc.2023.10.030","article-title":"Hyperuricemia and gout reduction by SGLT2 inhibitors in diabetes and heart failure: JACC review topic of the week","volume":"83","author":"Packer","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108973_bb0750","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022222","article-title":"Sodium-glucose co-transporter inhibitors and atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Pandey","year":"2021","journal-title":"Journal of the American Heart Association"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108973_bb0755","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/ejhf.2884","article-title":"Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study","volume":"25","author":"Pascual-Figal","year":"2023","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0760","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3389\/fphys.2020.00912","article-title":"Sodium-glucose cotransporter 2 inhibitors potentially prevent atrial fibrillation by ameliorating ion handling and mitochondrial dysfunction","volume":"11","author":"Peng","year":"2020","journal-title":"Frontiers in Physiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb0765","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/dom.13077","article-title":"Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study","volume":"20","author":"Persson","year":"2018","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"22","key":"10.1016\/j.pharmthera.2025.108973_bb0770","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","article-title":"Cardiac late sodium channel current is a molecular target for the sodium\/glucose cotransporter 2 inhibitor empagliflozin","volume":"143","author":"Philippaert","year":"2021","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108973_bb0775","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.2337\/dci22-0014","article-title":"Heart failure: An underappreciated complication of diabetes. A consensus report of the American Diabetes Association","volume":"45","author":"Pop-Busui","year":"2022","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb0780","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/cvr\/cvae047","article-title":"SGLT2 inhibitors: From glucose-lowering to cardiovascular benefits","volume":"120","author":"Preda","year":"2024","journal-title":"Cardiovascular Research"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108973_bb0785","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/jce.16369","article-title":"Relationship between sodium-glucose cotransporter 2 inhibitors and atrial fibrillation recurrence after pulmonary vein isolation in patients with type 2 diabetes and persistent atrial fibrillation","volume":"35","author":"Qi","year":"2024","journal-title":"Journal of Cardiovascular Electrophysiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb0790","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1080\/21655979.2021.2017652","article-title":"Protective effects of dapagliflozin on the vulnerability of ventricular arrhythmia in rats with pulmonary artery hypertension induced by monocrotaline","volume":"13","author":"Qin","year":"2022","journal-title":"Bioengineered"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108973_bb0795","first-page":"1833","article-title":"NADPH oxidases and oxidative stress in the pathogenesis of atrial fibrillation","volume":"12","author":"Ramos-Mondrag\u00f3n","year":"2023","journal-title":"Antioxidants (Basel, Switzerland)"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117984","article-title":"Two concurrent mechanisms are responsible for the INa increase produced by dapagliflozin and empagliflozin in healthy and heart failure cardiomyocytes","volume":"186","author":"Rap\u00fan","year":"2025","journal-title":"Biomedicine & pharmacotherapy"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108973_bb0805","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic insights of Empagliflozin in nondiabetic patients with HFrEF: From the EMPA-TROPISM study","volume":"9","author":"Requena-Ib\u00e1\u00f1ez","year":"2021","journal-title":"JACC. Heart Failure"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0810","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pharmtox-051421-111814","article-title":"CaMKII as a therapeutic target in cardiovascular disease","volume":"63","author":"Reyes Gaido","year":"2023","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"5861","key":"10.1016\/j.pharmthera.2025.108973_bb0815","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/297079a0","article-title":"Lipid-soluble toxins thought to be specific for Na+ channels block Ca2+ channels in neuronal cells","volume":"297","author":"Romey","year":"1982","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108973_bb0820","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb0825","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.115.018614","article-title":"Atrial fibrillation begets heart failure and vice versa: Temporal associations and differences in preserved versus reduced ejection fraction","volume":"133","author":"Santhanakrishnan","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb0830","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","article-title":"Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis\/stiffness in nondiabetic heart failure: A multimodality study","volume":"14","author":"Santos-Gallego","year":"2021","journal-title":"JACC. Cardiovascular Imaging"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108973_bb0835","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108973_bb0840","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.5551\/jat.48009","article-title":"The effect of Dapagliflozin treatment on Epicardial adipose tissue volume and P-wave indices: An ad-hoc analysis of the previous randomized clinical Trial","volume":"27","author":"Sato","year":"2020","journal-title":"Journal of Atherosclerosis and Thrombosis"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0845","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovascular Diabetology"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108973_bb0850","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/dme.13424","article-title":"Effect of sodium-glucose co-transporter-2 inhibitors on impaired ventricular repolarization in people with type 2 diabetes","volume":"34","author":"Sato","year":"2017","journal-title":"Diabetic Medicine: A Journal of the British Diabetic Association"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0855","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.00363.2025","article-title":"The sodium\/glucose cotransporter 2 inhibitor empagliflozin is a pharmacological chaperone of cardiac Nav1.5 channels","author":"Sauer","year":"2025","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb0860","doi-asserted-by":"crossref","first-page":"H418","DOI":"10.1152\/ajpheart.00729.2023","article-title":"Empagliflozin treatment rescues abnormally reduced Na+ currents in ventricular cardiomyocytes from dystrophin-deficient mdx mice","volume":"326","author":"Sauer","year":"2024","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108973_bb0865","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00125-020-05359-2","article-title":"Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: A meta-analysis","volume":"64","author":"Sayour","year":"2021","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108973_bb0870","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41574-020-0392-2","article-title":"Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus","volume":"16","author":"Scheen","year":"2020","journal-title":"Nature Reviews. Endocrinology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108973_bb0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2022.101390","article-title":"Antidiabetic agents and risk of atrial fibrillation\/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists","volume":"48","author":"Scheen","year":"2022","journal-title":"Diabetes & Metabolism"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108973_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2022.101405","article-title":"Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: A comprehensive review ranging from sulphonylureas to SGLT2 inhibitors","volume":"48","author":"Scheen","year":"2022","journal-title":"Diabetes & Metabolism"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0885","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-physiol-021317-121427","article-title":"The role of autophagy in the heart","volume":"80","author":"Sciarretta","year":"2018","journal-title":"Annual Review of Physiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb0890","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ejhf.3145","article-title":"Myocardial sodium-glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: The BIO-AS study","volume":"26","author":"Scisciola","year":"2024","journal-title":"European Journal of Heart Failure"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0895","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1038\/s41467-024-47850-z","article-title":"Cardiac function is regulated by the sodium-dependent inhibition of the sodium-calcium exchanger NCX1","volume":"15","author":"Scranton","year":"2024","journal-title":"Nature Communications"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb0900","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: A position statement from the heart failure Association of the European Society of cardiology","volume":"20","author":"Seferovi\u0107","year":"2018","journal-title":"European Journal of Heart Failure"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0905","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12933-019-0983-1","article-title":"Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: A Swedish cohort study","volume":"19","author":"Seyed Ahmadi","year":"2020","journal-title":"Cardiovascular Diabetology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108973_bb0910","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s10741-022-10281-3","article-title":"Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation\/atrial flutter in heart failure patients with reduced ejection fraction: A meta-analysis of randomized controlled trials","volume":"28","author":"Sfairopoulos","year":"2023","journal-title":"Heart Failure Reviews"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0915","first-page":"20","article-title":"Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: A meta-analysis of randomized controlled trials","volume":"24","author":"Sfairopoulos","year":"2022","journal-title":"Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology"},{"issue":"25","key":"10.1016\/j.pharmthera.2025.108973_bb0920","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1161\/CIRCULATIONAHA.120.052009","article-title":"Extracellular vesicles from epicardial fat facilitate atrial fibrillation","volume":"143","author":"Shaihov-Teper","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0925","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","article-title":"Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovascular Diabetology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb0930","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jacasi.2022.05.002","article-title":"Cause of death among patients with diabetes and heart failure with reduced ejection fraction","volume":"2","author":"Sharma","year":"2022","journal-title":"JACC. Asia"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108973_bb0935","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/CIRCRESAHA.113.302549","article-title":"Role of the autonomic nervous system in modulating cardiac arrhythmias","volume":"114","author":"Shen","year":"2014","journal-title":"Circulation Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0940","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: The EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovascular Diabetology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108973_bb0945","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/cvr\/cvt145","article-title":"The arrhythmogenic consequences of increasing late INa in the cardiomyocyte","volume":"99","author":"Shryock","year":"2013","journal-title":"Cardiovascular Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0950","doi-asserted-by":"crossref","first-page":"8689","DOI":"10.1038\/s41598-023-35944-5","article-title":"Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1","volume":"13","author":"Silva Dos Santos","year":"2023","journal-title":"Scientific Reports"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108973_bb0955","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0960","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9656078","article-title":"Cellular and molecular mechanisms of arrhythmia by oxidative stress","volume":"2016","author":"Sovari","year":"2016","journal-title":"Cardiology Research and Practice"},{"key":"10.1016\/j.pharmthera.2025.108973_bb0965","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.hjc.2024.03.008","article-title":"Efficacy of sodium-glucose cotransporter 2 inhibitors in preventing atrial fibrillation recurrence after catheter ablation","volume":"79","author":"Stachteas","year":"2024","journal-title":"Hellenic Journal of Cardiology: HJC = Hellenike Kardiologike Epitheorese"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108973_bb0970","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2337\/db19-0991","article-title":"Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating Sestrin2-mediated AMPK-mTOR signaling and redox homeostasis in high-fat diet-induced obese mice","volume":"69","author":"Sun","year":"2020","journal-title":"Diabetes"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108973_bb0975","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.3390\/jcm14155306","article-title":"SGLT2 inhibitors and the risk of arrhythmias in heart failure: A network Meta-analysis","volume":"14","author":"Suresh","year":"2025","journal-title":"Journal of Clinical Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0980","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12933-022-01508-6","article-title":"Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus","volume":"21","author":"Suzuki","year":"2022","journal-title":"Cardiovascular Diabetology"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108973_bb0985","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3390\/biom11121876","article-title":"Physiological and pathophysiological roles of mitochondrial Na+-Ca2+ exchanger, NCLX, in hearts","volume":"11","author":"Takeuchi","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb0990","doi-asserted-by":"crossref","first-page":"23","DOI":"10.15420\/ecr.2018.34.2","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors in heart failure: Potential mechanisms of action, adverse effects and future developments","volume":"14","author":"Tamargo","year":"2019","journal-title":"European Cardiology Review"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108973_bb0995","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1586\/erc.11.91","article-title":"Ranolazine: An antianginal drug with antiarrhythmic properties","volume":"9","author":"Tamargo","year":"2011","journal-title":"Expert Review of Cardiovascular Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb1000","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cardiores.2003.12.026","article-title":"Pharmacology of cardiac potassium channels","volume":"62","author":"Tamargo","year":"2004","journal-title":"Cardiovascular Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108973_bb1005","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s10554-020-02122-x","article-title":"Association of type 2 diabetes mellitus with the development of new-onset atrial fibrillation in patients with non-ischemic dilated cardiomyopathy: Impact of SGLT2 inhibitors","volume":"37","author":"Tanaka","year":"2021","journal-title":"The International Journal of Cardiovascular Imaging"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb1010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11325-022-02606-1","article-title":"Potential use of SGLT-2 inhibitors in obstructive sleep apnea: A new treatment on the horizon","volume":"27","author":"Tanriover","year":"2023","journal-title":"Sleep & Breathing = Schlaf & Atmung"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108973_bb1015","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.122.015176","article-title":"Empagliflozin improves left atrial strain in patients with type 2 diabetes: Data from a randomized, placebo-controlled study","volume":"16","author":"Thiele","year":"2023","journal-title":"Circulation. Cardiovascular Imaging"},{"issue":"16","key":"10.1016\/j.pharmthera.2025.108973_bb1020","doi-asserted-by":"crossref","first-page":"7642","DOI":"10.1111\/jcmm.16601","article-title":"Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPK\u03b1\/TGF-\u03b2\/Smad signalling in type 2 diabetic rats","volume":"25","author":"Tian","year":"2021","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108973_bb1025","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.hroo.2024.12.004","article-title":"Sodium-glucose cotransporter-2 inhibitor use in type 2 diabetes mellitus is associated with a lower rate of atrial arrhythmias in a hospitalized real-world population","volume":"6","author":"Tiver","year":"2025","journal-title":"Heart Rhythm O2"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108973_bb1030","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/cvr\/cvae095","article-title":"Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF","volume":"120","author":"Trum","year":"2024","journal-title":"Cardiovascular Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb1035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13578-021-00547-y","article-title":"Dapagliflozin attenuates hypoxia\/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK","volume":"11","author":"Tsai","year":"2021","journal-title":"Cell & Bioscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb1040","doi-asserted-by":"crossref","first-page":"15364","DOI":"10.1038\/s41598-021-94945-4","article-title":"Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"11","author":"Tsai","year":"2021","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2025.108973_bb1045","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2848759","article-title":"Molecular and electrophysiological mechanisms underlying cardiac arrhythmogenesis in diabetes mellitus","volume":"2016","author":"Tse","year":"2016","journal-title":"Journal of Diabetes Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108973_bb1050","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/medicina59101760","article-title":"Associations between oral glucose-lowering agents and increased risk for life-threatening arrhythmias in patients with type 2 diabetes mellitus-A literature review","volume":"59","author":"Tudoran","year":"2023","journal-title":"Medicina (Kaunas, Lithuania)"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb1055","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/2047487318755531","article-title":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","volume":"25","author":"Usman","year":"2018","journal-title":"European Journal of Preventive Cardiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108973_bb1060","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: Inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2025.108973_bb1065","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3389\/fphys.2018.01575","article-title":"Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients","volume":"9","author":"Uthman","year":"2018","journal-title":"Frontiers in Physiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb1070","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12933-024-02436-3","article-title":"Evidence of a bi-directional relationship between heart failure and diabetes: A strategy for the detection of glucose abnormalities and diabetes prevention in patients with heart failure","volume":"23","author":"Valensi","year":"2024","journal-title":"Cardiovascular Diabetology"},{"key":"10.1016\/j.pharmthera.2025.108973_bb1075","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annual Review of Physiology"},{"issue":"36","key":"10.1016\/j.pharmthera.2025.108973_bb1080","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"European Heart Journal"},{"issue":"21","key":"10.1016\/j.pharmthera.2025.108973_bb1085","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: The EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108973_bb1090","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nature Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108973_bb1095","first-page":"1381","article-title":"Could sodium\/glucose co-transporter-2 inhibitors have antiarrhythmic potential in atrial fibrillation?","volume":"81","author":"Vrachatis","year":"2021","journal-title":"Literature Review and Future Considerations. Drugs"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108973_bb1100","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jacc.2019.07.020","article-title":"Atrial fibrillation and diabetes mellitus: JACC review topic of the week","volume":"74","author":"Wang","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108973_bb1105","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1080\/1061186X.2022.2064479","article-title":"Empagliflozin alleviates myocardial I\/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK\/ATF4\/Beclin1 pathway","volume":"30","author":"Wang","year":"2022","journal-title":"Journal of Drug Targeting"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb1110","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.21037\/jtd-22-550","article-title":"The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation\/atrial flutter in patients with type 2 diabetes mellitus\/heart failure: A systematic review and meta-analysis","volume":"14","author":"Wang","year":"2022","journal-title":"Journal of Thoracic Disease"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108973_bb1115","doi-asserted-by":"crossref","first-page":"258","DOI":"10.31083\/j.rcm2409258","article-title":"Association of sodium-glucose cotransporter 2 inhibitors (SGLT2i) with cardiac arrhythmias: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"24","author":"Wang","year":"2023","journal-title":"Reviews in Cardiovascular Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb1120","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12933-018-0768-y","article-title":"Type 2 diabetes is independently associated with all-cause mortality secondary to ventricular tachyarrhythmias","volume":"17","author":"Weidner","year":"2018","journal-title":"Cardiovascular Diabetology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb1125","doi-asserted-by":"crossref","first-page":"15683","DOI":"10.1038\/s41598-024-66098-7","article-title":"Empagliflozin rescues pro-arrhythmic and Ca2+ homeostatic effects of transverse aortic constriction in intact murine hearts","volume":"14","author":"Wen","year":"2024","journal-title":"Scientific Reports"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108973_bb1130","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3390\/cells8101202","article-title":"Mitochondrial dysfunction underlies cardiomyocyte remodeling in experimental and clinical atrial fibrillation","volume":"8","author":"Wiersma","year":"2019","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108973_bb1135","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108973_bb1140","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1369250","article-title":"Divergent electrophysiologic action of dapagliflozin and empagliflozin on ventricular and atrial tachyarrhythmias in isolated rabbit hearts","volume":"11","author":"Wolfes","year":"2024","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb1145","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12933-022-01614-5","article-title":"Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling","volume":"21","author":"Wu","year":"2022","journal-title":"Cardiovascular Diabetology"},{"key":"10.1016\/j.pharmthera.2025.108973_bb1150","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.934193","article-title":"Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study","volume":"9","author":"Wu","year":"2022","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108973_bb1155","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/ph15070875","article-title":"Na+\/H+ exchanger 1, a potential therapeutic drug target for cardiac hypertrophy and heart failure","volume":"15","author":"Xia","year":"2022","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"10.1016\/j.pharmthera.2025.108973_bb1160","article-title":"Mitochondrial oxidative stress promotes atrial fibrillation","volume":"5","author":"Xie","year":"2015","journal-title":"Scientific Reports"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108973_bb1165","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s00392-024-02386-6","article-title":"Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized placebo-controlled trials","volume":"113","author":"Xu","year":"2024","journal-title":"Clinical Research in Cardiology: Official Journal of the German Cardiac Society"},{"key":"10.1016\/j.pharmthera.2025.108973_bb1170","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.988408","article-title":"Sodium-glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice","volume":"13","author":"Xue","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108973_bb1175","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1042\/CS20190585","article-title":"Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice","volume":"133","author":"Xue","year":"2019","journal-title":"Clinical Science (London, England\u202f: 1979)"},{"issue":"20","key":"10.1016\/j.pharmthera.2025.108973_bb1180","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/CIRCULATIONAHA.118.035202","article-title":"Enhanced cardiomyocyte NLRP3 Inflammasome signaling promotes atrial fibrillation","volume":"138","author":"Yao","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108973_bb1185","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/jcp.26760","article-title":"Sodium-glucose cotransporter inhibitors and oxidative stress: An update","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"Journal of Cellular Physiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb1190","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 inhibition with Dapagliflozin reduces the activation of the NLRP3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10.1016\/j.pharmthera.2025.108973_bb1195","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.902923","article-title":"Effect of sodium-glucose co-transporter protein 2 inhibitors on arrhythmia in heart failure patients with or without type 2 diabetes: A meta-analysis of randomized controlled trials","volume":"9","author":"Yin","year":"2022","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108973_bb1200","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3390\/biomedicines13061484","article-title":"Ketone body induction: Insights into metabolic disease management","volume":"13","author":"Yoo","year":"2025","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108973_bb1205","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","article-title":"Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction","volume":"21","author":"Yurista","year":"2019","journal-title":"European Journal of Heart Failure"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108973_bb1210","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of Dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: Insights from the DECLARE-TIMI 58 Trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"issue":"40","key":"10.1016\/j.pharmthera.2025.108973_bb1215","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"European Heart Journal"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108973_bb1220","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/eurjpc\/zwad356","article-title":"Sodium-glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: A systemic review and meta-analysis","volume":"31","author":"Zhang","year":"2024","journal-title":"European Journal of Preventive Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb1225","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12933-019-0914-1","article-title":"Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction","volume":"18","author":"Zhang","year":"2019","journal-title":"Cardiovascular Diabetology"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108973_bb1230","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1093\/eurjpc\/zwab173","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: A systematic review and meta-analysis","volume":"28","author":"Zhang","year":"2022","journal-title":"European Journal of Preventive Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb1235","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/ijms24010858","article-title":"Canagliflozin attenuates lipotoxicity in cardiomyocytes by inhibiting inflammation and Ferroptosis through activating AMPK pathway","volume":"24","author":"Zhang","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"24","key":"10.1016\/j.pharmthera.2025.108973_bb1240","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031269","article-title":"Impact of sodium-glucose cotransporter 2 inhibitor on recurrence after catheter ablation for atrial fibrillation in patients with diabetes: A propensity-score matching study and Meta-analysis","volume":"12","author":"Zhao","year":"2023","journal-title":"Journal of the American Heart Association"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108973_bb1245","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.hrthm.2024.08.034","article-title":"Impact of sodium-glucose cotransporter 2 inhibitor on recurrence and cardiovascular outcomes after catheter ablation for atrial fibrillation in patients with heart failure","volume":"22","author":"Zhao","year":"2025","journal-title":"Heart Rhythm"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108973_bb1250","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s12551-020-00742-0","article-title":"The molecular mechanisms associated with the physiological responses to inflammation and oxidative stress in cardiovascular diseases","volume":"12","author":"Zhazykbayeva","year":"2020","journal-title":"Biophysical Reviews"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb1255","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1097\/FJC.0000000000001183","article-title":"Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: A systemic review and meta-analysis of randomized controlled trials","volume":"79","author":"Zheng","year":"2022","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108973_bb1260","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/pace.14880","article-title":"Effect of SGLT2 inhibitors on cardiovascular events in patients with atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials","volume":"47","author":"Zheng","year":"2024","journal-title":"Pacing and Clinical Electrophysiology: PACE"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108973_bb1265","doi-asserted-by":"crossref","first-page":"10887","DOI":"10.21037\/apm-21-2694","article-title":"Sodium-glucose cotransporter-2 inhibitors protect against atrial fibrillation in patients with heart failure","volume":"10","author":"Zhou","year":"2021","journal-title":"Annals of Palliative Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108973_bb1270","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/STROKEAHA.120.031623","article-title":"Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis","volume":"52","author":"Zhou","year":"2021","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108973_bb1275","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/STROKEAHA.118.023009","article-title":"Canagliflozin and stroke in type 2 diabetes mellitus","volume":"50","author":"Zhou","year":"2019","journal-title":"Stroke"},{"issue":"22","key":"10.1016\/j.pharmthera.2025.108973_bb1280","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"The New England Journal of Medicine"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825001858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825001858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:39:57Z","timestamp":1773974397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725825001858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":260,"alternative-id":["S0163725825001858"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108973","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitors: Do they have antiarrhythmic properties?","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108973","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108973"}}